Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
|ClinicalTrials.gov Identifier: NCT01155817|
Recruitment Status : Unknown
Verified May 2013 by David Miklos, Stanford University.
Recruitment status was: Active, not recruiting
First Posted : July 2, 2010
Last Update Posted : May 7, 2013
Information provided by (Responsible Party):
David Miklos, Stanford University
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||July 2013|
|Estimated Study Completion Date :||July 2014|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, Beumer JH, Qiu J, Cerda K, Le R, Otani JM, Liu H, Ross MA, Arai S, Flowers MED, McCarthy PL, Miklos DB. Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant. 2018 Feb;24(2):373-380. doi: 10.1016/j.bbmt.2017.10.021. Epub 2017 Oct 16.